<div id="readability-page-1"><div><h2>Why Abbisko Cayman's Latest Earnings Matter for Investors</h2> <p>Abbisko Cayman (SEHK:2256) is back in focus after releasing full year 2025 results, reporting sales of CNY612.12 million and net income of CNY55.25 million, alongside basic and diluted EPS of CNY0.09 from continuing operations.</p> <p>See our latest analysis for Abbisko Cayman.</p> <p>The earnings release appears to have shifted sentiment in the short term, with a 1 day share price return of 4.76% to HK$11.88. However, the 90 day share price return of 16.63% and the year to date share price return of an 8.76% decline contrast with a 1 year total shareholder return of 56.32% and a 3 year total shareholder return of around 3.7x, suggesting longer term holders have seen stronger momentum than recent traders.</p> <p>If Abbisko Cayman's swing in sentiment has your attention, it could be a good moment to broaden your watchlist with 120 healthcare AI stocks sourced from the Simply Wall St screener.</p> <p>With Abbisko Cayman trading at HK$11.88 and an indicated intrinsic value gap plus a large discount to analyst targets, the key question for you is whether this is a genuine mispricing or whether markets are already incorporating expectations about future growth.</p> <h2>Preferred P/E of 127.6x: Is It Justified?</h2> <p>On a headline basis, Abbisko Cayman’s current valuation looks stretched, with a P/E of 127.6x at a last close of HK$11.88 compared with both peers and the wider Asian biotech space.</p> <p>The P/E multiple compares the share price to earnings per share, so a higher ratio often reflects the market pricing in strong future profitability or assigning a premium for perceived quality. For Abbisko Cayman, this rich multiple sits against forecasts that earnings may decline by an average of 124.6% per year over the next three years and expectations that the company could be unprofitable in that timeframe. This raises questions about how durable this valuation is if those forecasts play out.</p> <p>When you stack Abbisko Cayman’s 127.6x P/E against the Asian biotech industry average of 39.5x and a peer average of 47.5x, the gap is wide. The estimated fair P/E ratio of 2.6x points to a level the market could move closer to if sentiment or expectations shift.</p> <p>Explore the SWS fair ratio for Abbisko Cayman</p> <p><strong>Result: Price-to-Earnings of 127.6x (OVERVALUED)</strong></p> <p>However, you also need to weigh risks like forecast earnings declines alongside Abbisko Cayman’s broad, capital intensive R&amp;D pipeline, which could challenge sentiment if timelines or outcomes disappoint.</p> <p>Find out about the key risks to this Abbisko Cayman narrative.</p> <h2>Another View: DCF Signals A Very Different Story</h2> <p>While the current P/E of 127.6x looks heavy, our DCF model points the other way and suggests Abbisko Cayman at HK$11.88 is trading well below an estimated future cash flow value of HK$36.25. That gap frames the debate: is the market too cautious on long term cash generation?</p> <p>Look into how the SWS DCF model arrives at its fair value.</p> <figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/1b6fe608-cd42-4f1d-8b8b-4b3d6093f0d4/chart/dcf/query-ZGF0ZT0yMDI2LTAzLTA4?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/1b6fe608-cd42-4f1d-8b8b-4b3d6093f0d4/chart/dcf/query-ZGF0ZT0yMDI2LTAzLTA4"/><figcaption>2256 Discounted Cash Flow as at Mar 2026</figcaption></figure><p>Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Abbisko Cayman for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 222 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.</p> <h2>Next Steps</h2> <p>If this mix of signals feels mixed to you, it may be a good time to review the numbers yourself and decide where you stand, starting with 3 key rewards and 1 important warning sign.</p> <h2>Looking for more investment ideas?</h2> <p>If Abbisko Cayman is on your radar, do not stop there. The market is full of other angles that could round out your watchlist and sharpen your decisions.</p> <ul> <li>Target potential mispricings by reviewing our list of 222 high quality undervalued stocks that pair attractive prices with solid underlying fundamentals.</li> <li>Strengthen the income side of your portfolio by checking out 463 dividend fortresses, focused on companies offering 5%+ yields that aim to balance payout and resilience.</li> <li>Protect your downside by scanning 299 resilient stocks with low risk scores, a set of resilient names with lower risk scores that could help steady overall portfolio volatility.</li> </ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data     and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your     financial situation. We aim to bring you long-term focused analysis driven by fundamental data.     Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.     Simply Wall St has no position in any stocks mentioned.</em></p><div><h3><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>• Connect an unlimited number of Portfolios and see your total in one currency<br/>• Be alerted to new Warning Signs or Risks via email or mobile<br/>• Track the Fair Value of your stocks<br/></p><p>Try a Demo Portfolio for Free</p></div></div></div>

02256

<p>Abbisko Cayman (SEHK:2256) reported full year 2025 results with sales of CNY612.12 million and net income of CNY55.25 million, leading to a basic EPS of CNY0.09. The stock saw a 4.76% increase to HK$11.88 post-release, but has a 90-day return of 16.63% and a year-to-date decline of 8.76%. The current P/E ratio of 127.6x is significantly higher than industry averages, raising concerns about its valuation amidst forecasts of declining earnings. However, a DCF analysis suggests a potential fair value of HK$36.25, indicating possible market caution on long-term cash generation.</p>

Assessing Abbisko Cayman (SEHK:2256) Valuation After Full Year 2025 Earnings Release